Humacyte Earnings Call Transcripts
Fiscal Year 2026
-
First quarter Symvess sales grew fivefold year-over-year, driven by expanded U.S. and international efforts, new leadership, and a revamped commercial strategy. Interim phase III dialysis trial results are expected in June, with a supplemental BLA planned for late 2026.
-
ATEV showed superior usability, durability, and safety over AV fistula in women with ESKD, reducing catheter dependence and related complications. Adoption is expected to expand from high-risk groups as clinical experience and supportive payment models grow.
-
Launch of a first-in-class vascular product led to key learnings in hospital adoption, pricing, and education, with strong clinical evidence supporting trauma and dialysis indications. Expansion into dialysis and coronary markets is underway, with CMS engagement and Fresenius collaboration supporting growth.
-
A novel engineered vessel platform demonstrated strong clinical and economic value in trauma and dialysis, with FDA approval and market launch achieved. Ongoing trials target expanded indications, including a women-focused dialysis study and a CABG trial, with promising preclinical results and continued sales growth anticipated.
Fiscal Year 2025
-
Symvess commercial adoption accelerated in 2025 with strong VAC approval rates, U.S. DoD funding, and international expansion, while financials improved with reduced net loss and increased cash reserves. Pipeline progress continues in dialysis access and coronary applications.
-
Q3 2025 saw strong commercial momentum for Symvess, with sales rising to $703,000 and 92 hospitals eligible to purchase. Cost savings and a $56.5M capital raise extended cash runway beyond 12 months, while new clinical data and publications supported further adoption and pipeline progress.
-
Symvess expanded rapidly into over 200 eligible hospitals, with strong July sales and new military access via ECAT. Q2 revenue reached $0.3M, and cost-saving measures are expected to yield over $50M through 2026. Focus remains on commercial growth, pipeline progress, and private payer reimbursement.
-
SYMVESS, an engineered vascular graft, launched after FDA approval, shows superior clinical outcomes and is targeting a focused trauma market. Sales are expected to ramp in the second half of the year, with a key Medicare reimbursement decision pending. Cash runway extends through 2026.
-
FDA-approved CIMVEST launched commercially, with 45 hospitals evaluating and five approving purchases. Q1 2025 revenue reached $517,000, and net income was $39.1 million, aided by a non-cash gain. Most sales are expected in the second half of 2025.
-
Symvess, a bioengineered vascular graft, has officially launched after FDA approval, targeting trauma and PAD markets with strong clinical and economic data. Surgeons report positive outcomes and anticipate broader adoption as more sizes and long-term data become available.
-
FDA-approved Symvess launched commercially, targeting trauma and dialysis access markets with strong clinical data showing reduced complications and cost savings. Early adoption is underway, with sales expected to accelerate in the year's second half.
Fiscal Year 2024
-
FDA approval and commercial launch of SYMVESS drove a landmark year, with strong early hospital adoption and first commercial revenues. R&D and G&A expenses rose year-over-year, but new funding and a positive budget impact model support future growth.
-
A regenerative medicine platform has shown strong clinical results in trauma and dialysis, with lower complication rates and durable outcomes. Regulatory review is ongoing, with product launch possible within weeks of approval. Economic models support broad adoption and cost-effectiveness.
-
HAV BLA for vascular trauma remains under FDA review, with commercial preparations ongoing and strong clinical data supporting multiple indications. Financials show increased R&D and G&A expenses, a reduced net loss sequentially, and a strengthened cash position following recent capital raises.
-
A regenerative tissue platform has reached commercial-scale manufacturing, with engineered arteries showing strong clinical results in trauma and dialysis access, including superior usability and durability. Regulatory review is ongoing, commercialization plans are advanced, and further clinical milestones are expected soon.
-
A first-in-class acellular tissue vessel platform demonstrated strong clinical outcomes in trauma and dialysis access, with FDA approval anticipated soon. Commercial-scale manufacturing is in place, and strategic partnerships are set to drive adoption in key markets.
-
ATEV's FDA review for vascular trauma is delayed, but commercial launch preparations and pipeline progress continue. Positive phase 3 results in hemodialysis access and new RMAT designation in PAD highlight broad potential, while cash position is bolstered by recent financing.
-
A novel engineered vessel platform is nearing FDA approval for trauma, with strong clinical data showing reduced infection and amputation rates. Commercial launch will target major trauma centers, leveraging scalable manufacturing and a price point around $25,000 per vessel.